Q-omics provides the consensus-scored DPPA5P4 profile across patient tissues and cancer cell-line models. DPPA5P4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, DPPA5P4 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, DPPA5P4 protein abundance shows 14,398 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUSC, THCA, and GBM as cancer lineages where DPPA5P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DPPA5P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DPPA5P4 survival associations across molecular data types. DPPA5P4 RNA expression shows survival associations in the most cancer types (19), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DPPA5P4 RNA expression–survival associations across cancer types. High DPPA5P4 expression shows unfavorable associations in LUSC, MESO, COAD, DLBC and ACC, but favorable associations in SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify LUSC as the clearest survival context for DPPA5P4 RNA expression.
This table summarizes DPPA5P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DPPA5P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DPPA5P4 shows lower tumor expression in THCA, BRCA, LUSC and LIHC. The THCA box plot shows higher DPPA5P4 RNA expression in normal versus tumor tissue (log2 FC = −0.948, t-test p < 0.001).
This table shows molecular features associated with DPPA5P4 in patient tissues and cancer cell lines. In patient samples, DPPA5P4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
